3rd generation glp 1 agonist There's a new name in the conversation — and it's worth paying attention to. Retatrutide is a triple-agonist therapy that targets GLP-1, GIP, and glucagon receptors simultaneously. In clinical trials, it GLP-1 agonists and changes in

1c,e), and no detectable affinity for NADH (Fig

BPC-157 BPC-157, short for Body Protection Compound 157, is a synthetic pentadecapeptide composed of 15 amino acids and supplied as a high-purity lyophilized powder

The suppressing effect of GLP-1 on alcohol intake is linked to suppressed alcohol reward, an idea now tested in both rats and mice with two different tests of alcohol reward behavior, adding strength to the conclusion

RF: Thats a cute analogy

This doesnt necessarily mean GLP-1s are bad, but there is a chance that future safety concerns will surface

In April 2026, a federal policy change altered the regulatory classification of 12 of these peptides, a move ECRI and ISMP caution was not accompanied by new clinical evidence and should not be interpreted as a safety endorsement